Fever Clinical Trial
Official title:
Efficacy and Safety Study of Caldolor in Hospitalized Febrile Pediatric Patients
Verified date | October 2007 |
Source | Cumberland Pharmaceuticals |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
The primary objective of this study of Caldolor administered to febrile hospitalized pediatric patients every 6 hours for 24 hours is to determine the clinical equivalence of a single dose of Caldolor compared to acetaminophen (paracetamol; APAP) for the treatment of fever as measured by the AUC Tº within the first 6 hours of treatment (as compared to a target temperature of 98.6ºF [37.0ºC]).
Status | Completed |
Enrollment | 0 |
Est. completion date | August 2007 |
Est. primary completion date | August 2007 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 6 Months to 17 Years |
Eligibility |
Inclusion Criteria: 1. Be hospitalized 2. Be between 6 months and 17 years of age, inclusive 3. Have new (not chronic, within last 7 days) onset of fever, documented by temperature greater than or equal to 101.0ºF (38.3ºC) (The preferred method of temperature measurement is core. The route of temperature measurement used immediately before randomization should be used immediately before dosing and for all temperature measurements during the Treatment Period.) 4. Have written informed consent provided by legal parent, guardian, or authorized agent, and have same agree to abide by the study restrictions and to return for the required assessments (Where appropriate, participants of appropriate intellectual maturity should personally provide written informed assent; age of assent may be determined by Institutional Review Boards (IRBs) or Independent Ethics Committees (IECs) or be consistent with local legal requirements.) Exclusion Criteria: 1. Have inadequate intravenous access 2. Have received antipyretic drug therapy within 8 hours before dosing 3. Be pregnant or nursing 4. Have any history of allergy or hypersensitivity to NSAIDs, aspirin, APAP, or any component of Caldolor or APAP. 5. Have a history of severe head trauma that required the current hospitalization, had intracranial surgery or stroke within the previous 30 days, or have any history of intracerebral arteriovenous malformation, cerebral aneurysm, or central nervous system mass lesions 6. Have a history of febrile convulsion or have a sibling with a history of febrile convulsion 7. Have a history of congenital bleeding diatheses (e.g., hemophilia) or any active clinically significant bleeding, or have underlying platelet dysfunction, including (but not limited to) idiopathic thrombocytopenic purpura, disseminated intravascular coagulation, or congenital platelet dysfunction 8. Have gastrointestinal bleeding that has required medical intervention within the previous 6 weeks, unless definitive surgery has been performed 9. Have platelet count less than 30,000/mm3 10. Be receiving full dose anticoagulation therapy (Prophylaxis with subcutaneous heparin is acceptable.) 11. Have fever secondary to blood or drug reaction 12. Have an expected life span of less than 14 days because of imminent withdrawal of life support or severity of illness 13. Be receiving ongoing or imminent treatment with corticosteroids 14. Have neurogenic fever 15. Be on dialysis, have oliguria or calculated creatinine clearance of less than 70 mL/min (calculated using the Schwartz formula), have impaired renal function, be receiving nephrotoxic drugs, or be expected to be unable to tolerate the extra fluid required for administration of CTM 16. Have had major surgery within the past 12 hours, unless adequate hemostasis has been achieved 17. Have received another investigational drug within the past 30 days 18. Be otherwise unsuitable for the study, in the opinion of the Investigator |
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Panama | Hospital Cecilio Castillero | Chitre | Herrera |
South Africa | Unitas Hospital | Lyttleton | Pretoria |
United States | Vanderbilt University Children's Hospital | Nashville | Tennessee |
Lead Sponsor | Collaborator |
---|---|
Cumberland Pharmaceuticals |
United States, Panama, South Africa,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Temperature |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02948283 -
Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Completed |
NCT03706599 -
Fever Infants and Therapeutic Education in Emergency Department
|
N/A | |
Not yet recruiting |
NCT05649891 -
Checklists Resuscitation Emergency Department
|
N/A | |
Not yet recruiting |
NCT01782183 -
Thermographic Characteristics of Sore Throat by Thermographic Camera
|
N/A | |
Withdrawn |
NCT00800696 -
Preventive Oral Care
|
N/A | |
Completed |
NCT02689193 -
IDIS Project Work Package 2: Establishing a Biobank at ITM and Collaborating Centres
|
||
Completed |
NCT02212990 -
The Effect of Prophylactic Antipyretics on Immune Responses and Fever After 2014-2015 and 2015-2016 Inactivated Influenza Vaccine
|
N/A | |
Completed |
NCT01911143 -
A Retrospective, Blinded Validation of a Host-response Based Diagnostics
|
N/A | |
Completed |
NCT01869699 -
Effects of Intravenous Acetaminophen on Body Temperature and Hemodynamic Responses in Febrile Critically Ill Adults
|
Phase 4 | |
Completed |
NCT01559675 -
Trial Comparing Low Dose and High Dose Steroids in Patients Undergoing Colorectal Surgery
|
N/A | |
Completed |
NCT01194557 -
Introducing Rapid Diagnostic Tests Into the Private Health Sector
|
N/A | |
Completed |
NCT00969176 -
Pharmacokinetics, -Dynamics and Safety of Intravenous Paracetamol in Neonates
|
Phase 2/Phase 3 | |
Completed |
NCT00940654 -
The Fever and Antipyretic in Critically Illness Evaluation Study
|
N/A | |
Recruiting |
NCT00729976 -
Oral Versus Rectal Ibuprofen for Fever in Young Children - a Randomized Control Study.
|
Phase 4 | |
Recruiting |
NCT00389272 -
Adding a Second Drug for Febrile Children Treated With Acetaminophen
|
N/A | |
Completed |
NCT00257790 -
The Tobramycin Study
|
Phase 4 | |
Recruiting |
NCT05033613 -
Home Blood Pressure Monitoring Before and After COVID-19 Vaccination in Patients at High Risk of Cardiovascular Disease
|
||
Completed |
NCT02595827 -
Non-inferiority Trial of Conditional vs Universal Follow up for Children With Fever in Democratic Republic of Congo
|
Phase 3 | |
Recruiting |
NCT06061575 -
Comparison of the Efficacy of Paracetamol and Ibuprofen in the Management of Fever in Sepsis Patients
|
Phase 4 | |
Recruiting |
NCT06038617 -
Safety of Simultaneous mRNA COVID-19 Vaccine With Other Childhood Vaccines in Young Children
|
Phase 4 |